HealOr is a biopharmaceutical company committed to the development and commercialization of proprietary therapeutics impacting skin cells' properties for the purpose of treating various skin pathologies.

HealOr has completed a safety and primary efficacy study of its lead drug HO/03/03 a topical drug for the treatment of diabetic foot ulcers and venous leg ulcers. HO/03/03 is expected to enter additional clinical trials in Q1/2009.

Pioneering a new, comprehensive approach to skin care, HealOr is establishing a first-in-class therapeutic pipeline for additional skin pathologies such as acute/post surgical wounds, scar prevention and wound prevention of "skin at risk" as well as aged-skin-related disorders.